Inactive Instrument

Akili, Inc.

AKLI

US00974B1070

Advanced Medical Equipment & Technology

Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment

Published on 06/18/2024 at 04:36 pm EDT - Modified on 06/18/2024 at 04:49 pm EDT

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Akili, Inc.

24-07-02	Akili, Inc., Virtual Therapeutics Corporation and Alpha Merger Sub, Inc Announce Management Changes	CI
24-07-01	Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index	CI
24-07-01	Virtual Therapeutics Corp. completed the acquisition of Akili, Inc. from SC Master Holdings, LLC, SC Pipe Holdings LLC, Chamath Palihapitiya and others.	CI
24-07-01	Akili, Inc.(NasdaqCM:AKLI) dropped from S&P TMI Index	CI
24-06-18	Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment	MT
24-06-18	Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game	CI
24-06-18	Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment	DJ
24-05-29	PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company	MT
24-05-28	Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million.	CI
24-05-14	Akili, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-14	Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M	MT
24-04-30	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
24-04-30	Akili, Inc. to Reduce Workforce	CI
24-04-30	Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	CI
24-02-29	Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâ€™s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company